Improving

Human Health

We invest in early-stage life-science companies with the potential to enhance human well-being and quality of life.

ABOUT US LET'S TALK

Continuing to

Grow & Invest

We are an evergreen fund that has a long-term investment perspective.

OUR APPROACH LET'S TALK

Focusing on the

Mid-Atlantic Region

We invest in life-science companies in the Mid-Atlantic region.

OUR CRITERIA LET'S TALK

Launching Successful

Companies

Our portfolio companies have attracted over $4.4 billion of external capital to support their growth.

OUR PORTFOLIO LET'S TALK

Latest News

All Accelerated Biosciences Acuity Pharmaceuticals Allevi Alteris Annovis Atalan Avid Radiopharmaceuticals Bainbridge Health BioAdvance News BobcatBio Ceptaris Cohero Health Concarlo Therapeutics CrossBridge Eliksa Therapeutics ENB Therapeutics General Halo Labs Hanimune Therapeutics HealthQx HueDx ImmunoGenesis Immunome InfraScan Innervace Intezyne iView Therapeutics KaloCyte Kayothera Keriton Ladder Bio Latus LumenVu Mebias Discovery Melior Discovery Midway Pharmaceuticals Novira Therapeutics NuPathe Oncora Medical Onspira Therapeutics Opsidio Ossianix Palvella Therapeutics Phrase Health Pillo Health Portfolio News Protez Pharmaceuticals PST Relmada Therapeutics Renovacor Ride Health Senzo Strados The One Health Company Tolerance Bio Treventis Corporation Venatorx Pharmaceuticals Vesteck Vittoria Biotherapeutics Wellsheet

The Coalition for Physician & APP Well-Being Launches “The Initiative Intelligence Guide” to Help Health Systems Better Evaluate Workforce, Retention, and Operational Initiatives

Atalan Launches Nurse Retention Platform Designed to Identify Risk Up to 12 Months in Advance

Beyond Celiac Investments Announces Investment in Tolerance Bio to Advance Novel Approach in Celiac Disease

Latus Bio Appoints Bethany Mancilla as Chief Business Officer

Who We Are

OUR COMPANY

Who We Support

OUR PORTFOLIO